{"entity":{"id":"nct05204862","kind":"trial","name":"Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of TU2218 in advanced solid tumours, run by TiumBio Co., Ltd., now recruiting.","summary":"Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05204862 by TiumBio Co., Ltd., with 240 participants planned, started 2021-12-02 and due to reach its primary completion in 2026-06-30. Interventions recorded: TU2218 and Anti-PD-1 antibody.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05204862","url":"https://clinicaltrials.gov/study/NCT05204862"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["tiumbio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05204862","phase":"1/2","setting":"A Phase 1/2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Inhibitor, Administered Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","sponsor":"TiumBio Co., Ltd.","enrolled":240,"outcomes":[]},"route":"/trials/nct05204862/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"tiumbio","kind":"company","name":"TiumBio","route":"/companies/tiumbio/"}]}}